Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Teva Pharmaceuticals and Alvotech announced FDA approval for Simlandi, an interchangeable biosimilar to AbbVie's Humira, for various conditions. Simlandi, exclusively commercialized by Teva in the U.S., is the first high-concentration, citrate-free biosimilar to Humira with interchangeability status. This allows pharmacy-level substitution without prescriber consultation. Teva and Alvotech's strategic partnership, initiated in 2020, was recently extended. Additionally, Teva formed a partnership with Jiangsu Nhwa Pharmaceutical for the marketing of Austedo. Following the news, TEVA and ALVO stocks saw significant premarket gains.
February 26, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Humira faces new competition from Teva and Alvotech's FDA-approved interchangeable biosimilar, Simlandi.
The approval of Simlandi as an interchangeable biosimilar to Humira introduces significant competition for AbbVie, potentially affecting its market share and revenue from Humira, especially given Humira's substantial sales figures.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Alvotech, in partnership with Teva Pharmaceuticals, receives FDA approval for Simlandi, an interchangeable biosimilar to Humira. ALVO shares are up 11.6%.
Alvotech's partnership with Teva for the commercialization of Simlandi, now FDA approved, positions ALVO for significant market penetration, reflected by the premarket stock price increase.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Teva Pharmaceuticals gains FDA approval for Simlandi, a biosimilar to Humira, in partnership with Alvotech, and forms a new partnership for Austedo's marketing. TEVA shares are up 4.81%.
The FDA approval of Simlandi, a significant product in partnership with Alvotech, and the new marketing partnership for Austedo, are likely to positively impact TEVA's stock in the short term due to the potential for increased market share and revenue.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100